Development and Preclinical Evaluation of the Novel Peptide-Based Tracer 68Ga-PDT01 for Noninvasive PET Imaging of PD-L1 Expression
Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13367-13379
DOI: 10.1021/acs.jmedchem.6c00316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.06.2026. Verfasst von Cong Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Aca…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Positron-Emission Tomography, Radiopharmaceuticals, Peptides. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Ministry of Education of the People's Republic of China, Chinese Academy of Medical Sciences, Science and Technology Department of Gansu Province.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) is a key mediator of tumor immune evasion and plays a critical role in tumor immunodiagnosis and immunotherapy. We developed a PD-L1–targeted peptide PET tracer, 68Ga-PDT01, incorporating a 2-substituted naphthyl group and 5-(trifluoromethyl)nicotinic acid to enhance tumor uptake and retention. 68Ga-PDT01 exhibited moderate binding affinity (KD = 304 ± 26 nM) and specific uptake in PD-L1–positive cells, which was blocked by excess unlabeled peptide. PET imaging demonstrated clear tumor visualization in multiple subcutaneous tumor models with tumor-to-muscle ratios >6.00 at 1 h postinjection. Tracer uptake increased ∼3.16-fold following cisplatin-induced PD-L1 upregulation, indicating sensitivity to dynamic PD-L1 modulation. These findings suggest that 68Ga-PDT01 enables accurate, noninvasive assessment of PD-L1 expression and holds translational potential for guiding PD-L1–targeted diagnosis and therapeutic monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, Lanzhou University, 2019RU066, Lanzhou, Gans…
- Gansu Isotope Laboratory, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
ORCID-Profile: Hailong Zhang, Rui Wang
Förderung
- Ministry of Education of the People's Republic of China
- Chinese Academy of Medical Sciences
- Science and Technology Department of Gansu Province
- Gansu Provincial Intellectual Property Office
Zitieren
APA
Wang, C., Yang, H., Fan, X., Yi, J., Chen, G., Zhou, G., Zhang, T., Long, J., Zhang, M., Li, H., Zhang, H., & Wang, R. (2026). Development and Preclinical Evaluation of the Novel Peptide-Based Tracer 68Ga-PDT01 for Noninvasive PET Imaging of PD-L1 Expression. Journal of Medicinal Chemistry, 69(11), 13367-13379. https://doi.org/10.1021/acs.jmedchem.6c00316
Vancouver
Wang C, Yang H, Fan X, Yi J, Chen G, Zhou G, et al. Development and Preclinical Evaluation of the Novel Peptide-Based Tracer 68Ga-PDT01 for Noninvasive PET Imaging of PD-L1 Expression. Journal of Medicinal Chemistry. 2026;69(11):13367-13379. doi:10.1021/acs.jmedchem.6c00316
BibTeX
@article{Wang2026,
author = {Wang, Cong and Yang, Hange and Fan, Xuegong and Yi, Juan and Chen, Gong and Zhou, Gangzhong and Zhang, Tao and Long, Juntao and Zhang, Mingyu and Li, Hongyan and Zhang, Hailong and Wang, Rui},
title = {Development and Preclinical Evaluation of the Novel Peptide-Based Tracer 68Ga-PDT01 for Noninvasive PET Imaging of PD-L1 Expression},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {11},
pages = {13367--13379},
doi = {10.1021/acs.jmedchem.6c00316}
}
EUVIMED